Atlanta Law Firm Helps Patients Injured by Gadolinium MRI Contrast Agents

Share Article

The Law Firm of Cash, Krugler and Fredericks (CKandF) is monitoring the increased scrutiny, warnings and drug label changes from the U.S. Food and Drug Administration (FDA) regarding the safety of injecting patients with kidney dysfunction with Gadolinium based contrast agents (GBCAs) during magnetic resonance imaging (MRI) procedures. The products are administered to patients to enhance the visibility of internal structures when undergoing MRIs. The warnings have come after a number of patients with kidney dysfunction that received GBCAs have contracted a rare but serious condition called Nephrogenic Systemic Fibrosis (NSF). NSF symptoms include scaling, hardening and tightening of the skin; red or dark patches on the skin; and stiffness. NSF has no cure and can be fatal. The FDA findings have resulted in product label changes to ensure that the drugs are administered properly and patients with kidney dysfunction are screened prior having an MRI with contrast procedures that use Gadolinium based agents.

Cash Krugler and Fredericks Atlanta Gadolinum Attorneys

The Law Firm of Cash, Krugler and Fredericks (CKandF) is monitoring the increased scrutiny, warnings and drug label changes from the U.S. Food and Drug Administration (FDA) regarding the use of Gadolinium-based contrast agents (GBCAs) during magnetic resonance imaging (MRI) procedures in patient with kidney dysfunction. These MRI dyes are administered to patients to enhance the visibility of internal structures when undergoing MRIs. The warnings have come after a number of patients with kidney dysfunction that received GBCAs have contracted a rare but serious condition called Nephrogenic Systemic Fibrosis (NSF). NSF symptoms include scaling, hardening and tightening of the skin; red or dark patches on the skin; and stiffness. NSF has no cure and can be fatal. The FDA findings have resulted in product label changes to ensure that the drugs are administered properly and patients with kidney dysfunction are screened prior to MRI procedures that may use Gadolinium agents.

CKandF Gadolinium Attorneys are monitoring cases involving five products approved for use in the United States that contain Gadolinium-based contrast agents. These products are Magnevist manufactured by Bayer Schering Pharma, Ominiscan from GE Healthcare, OptiMARK manufactured by Mallinckrodt, Inc., MultiHance and Prohance from Bracco Diagnostics Inc. If a patient has severe kidney disease and a doctor requests an MRI using a contrast agent, the patient should ask if contrast agent is essential to the MRI. Often an MRI can be conducted without the use of a contrast agent and still provide acceptable results. Individuals who have received any of these GBCAs, particularly those with kidney dysfunction, should watch for signs of NSF. If a patient has been administered a GBCA and suspects that they have the symptoms of NSF they should get immediate medical attention and contact Cash, Krugler and Fredericks for legal advice.

Patients injured by Gadolinium-based contrast agents may be able to take legal action against the GBCA manufacturer even though these potentially defective products have not been recalled by the U.S. FDA. CK&F’s Gadolinium Attorneys are extremely knowledgeable about GBCAs and their links to NSF. An injured client needs a skilled attorney if they have been administered a GBCA and are showing signs of Nephrogenic Systemic Fibrosis. NSF symptoms such as burning, itchy or swollen skin, hardening/tightening of the skin, swelling of the joints, yellowish eyes or yellow spots on the whites of the eyes, red or darkish spots on the skin, stiff joints, loss of movement in the joints, deep pain in the hips or ribs and muscle weakness. CK&F attorneys know the ins and outs of dealing with injury and wrongful death from defective pharmaceutical products. Even if a patient is not sure about the actual name of the GBCA they were administered, CK&F attorneys will help with the case. Patients that received an MRI and are experiencing side NSF symptoms effects should have their medical records examined to see if a GBCA was used during their MRI. If they were injected with a GBCA and developed Nephrogenic Systemic Fibrosis symptoms they may have grounds for legal action against the product’s manufacturer. Injured parties may be able to get compensation for medical expenses, pain and suffering, mental anguish and other losses. Because of statutes of limitations, it is important to contact a CK&F Gadolinium Attorney as quickly as possible.

Dave Krugler of Cash, Krugler and Fredericks commented on the growth of NSF cases caused by Gadolinium based agents. “The first cases of Nephrogenic Systemic Fibrosis were identified in the late 1990s and it appears that Gadolinium-based contrast agents may have been responsible for many more cases of NSF than previously thought. The increased scrutiny of these products by the FDA highlights how dangerous these Gadolinium based products are to individuals with kidney dysfunction that undergo MRIs. At CK&F we are focused on helping clients who have been injured from injections of GBCAs that caused NSF. We want to get them compensation for the debilitating effects of NSF.”

Cash, Krugler and Fredericks, Law Firm has expert attorneys to handle Medical Malpractice, Trucking Accidents, Car Accidents, Wrongful Death, Premises Liability, False Arrest and Defective Products cases. They are located at 5447 Roswell Road, NE, Atlanta, GA 30342 and can be reached at 404-659-1710. Website development and Search Engine Marketing Servcies provided by Interactive Search Marketing, Atlanta, GA.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Krugler
Visit website